case_images: PMC11810938_01
case_images: Images of the patient before and 1 year after alloHSCT. (A, B) Show patient's feet with xerosis cutis, lichenification, and warts pre-alloHSCT. (C) indicates weight and length gain after alloHSCT. Z-scores measure the distance from the 50th percentile via standard deviation. (D, E) Show healthy skin of both hands with resolution of eczema post-alloHSCT.
case_images: fimmu-15-1507494-g001.jpg
case_images: PMC11810938_01_fimmu-15-1507494-g001.jpg
case_images: f1
case_images: Figure 1 ). Furthermore, he suffered from recurrent sinopulmonary infections and one episode of severe catheter-related sepsis due to MRSA. He showed significant growth delay ( Figure 1 ). He caught up weight from -5.2 to -2.7 standard deviations from the 50th percentile and length from -4.6 to -2.9 ( Figure 1 ).
case_images: Timeline course of disease and symptoms pre- and post-alloHSCT. The figure illustrates the onset of symptoms in our patient. AIHA, autoimmune hemolytic anemia; MRSA, methicillin-resistant Staphylococcus aureus; COVID, coronavirus disease; shading indicates progress or regression; dark color refers to severity.
case_images: fimmu-15-1507494-g002.jpg
case_images: PMC11810938_01_fimmu-15-1507494-g002.jpg
case_images: f2
case_images: Evolving symptoms are displayed in  Figure 2 .
case_images: Effect of dupilumab, rituximab, and alloHSCT on IgE and IgG levels. The figure visualizes the level of immunoglobulins after immune-modulating therapy with dupilumab and rituximab. IgE, immunoglobulin E; IgG, immunoglobulin G; RTX, rituximab; alloHSCT, hematopoietic stem cell transplantation. IgE and IgG display decrease prior and after alloHSCT. At 1 year after alloHSCT, IgG shows normal levels. IgE decreased at 1 year and within the normal range at 2 years post-alloHSCT.
case_images: fimmu-15-1507494-g003.jpg
case_images: PMC11810938_01_fimmu-15-1507494-g003.jpg
case_images: f3
case_images: We observed a rapid decrease in IgE ( Figure 3 ). The effect of rituximab is shown through the course of IgG levels ( Figure 3 ).
case_images: Visual abstract of the review of the literature. Fifteen publications on DOCK8 deficiency treated with alloHSCT were available, including single- and multicenter studies. Red dots indicate the locations of participating centers. A focus lies on patients with at least 8 years of age. Two bar charts illustrate pre- and post-HSCT complications (%). GvHD, graft-versus-host-disease; HSCT, hematopoietic stem cell transplantation; VOD, veno-occlusive disease; y, year.
case_images: fimmu-15-1507494-g004.jpg
case_images: PMC11810938_01_fimmu-15-1507494-g004.jpg
case_images: f4
case_images: The literature review revealed 173 patients with DOCK8 deficiency who underwent alloHSCT ( Figure 4 ).